Elsevier

Clinical Therapeutics

Volume 44, Issue 4, April 2022, Pages 476-479
Clinical Therapeutics

Editorial
How Would You Like to Take Your Medicine 2 Times a Year? Paliperidone Palmitate Every 6 Months for the Maintenance Treatment of Schizophrenia

https://doi.org/10.1016/j.clinthera.2022.02.003Get rights and content

Section snippets

Acknowledgments

Both authors contributed to the writing and editing of this editorial manuscript

DECLARATION OF INTEREST

Dr Citrome has worked as a consultant for AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Teva, and University of Arizona; has performed one-off ad hoc consulting for individuals/entities conducting

References (22)

  • M Jaeger et al.

    Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists

    Psychiatry Res

    (2010)
  • PM Haddad et al.

    The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses

    Ther Adv Psychopharmacol

    (2018)
  • M Mathews et al.

    Comparison of relapse prevention with 3 different paliperidone formulations in patients with schizophrenia continuing versus discontinuing active antipsychotic treatment: a post-hoc analysis of 3 similarly designed randomized studies

    Neuropsychiatr Dis Treat

    (2020)
  • S Leucht et al.

    Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia

    J Clin Psychiatry

    (2006)
  • JM Kane et al.

    Optimizing treatment choices to improve adherence and outcomes in schizophrenia

    J Clin Psychiatry

    (2019)
  • PJ Weiden et al.

    Does half-life matter after antipsychotic discontinuation? a relapse comparison in schizophrenia with 3 different formulations of paliperidone

    J Clin Psychiatry

    (2017)
  • M Greene et al.

    Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder

    J Med Econ

    (2018)
  • J Mahlich et al.

    Time to treatment discontinuation in German patients with schizophrenia: long-acting injectables versus oral antipsychotics

    Clin Drug Investig

    (2021)
  • L. Citrome

    Long-acting injectable antipsychotics: what, when, and how

    CNS Spectr

    (2021)
  • I Clark et al.

    Newer formulations of risperidone: role in the management of psychotic disorders

    CNS Drugs

    (2020)
  • Janssen Pharmaceuticals, Inc. INVEGA HAFYERA (paliperidone palmitate) [Prescribing Information]. Available at:...
  • Cited by (0)

    View full text